Skip to main content
Contact Us
Subscribe
E-Edition
74°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Personalis Inc
(NQ:
PSNL
)
1.395
-0.035 (-2.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Personalis Inc
< Previous
1
2
3
4
Next >
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
July 12, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis Reports First Quarter 2022 Financial Results
May 04, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at Upcoming Investor Conferences
April 28, 2022
From
Personalis, Inc.
Via
Business Wire
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
April 26, 2022
From
Personalis
Via
Business Wire
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
April 21, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce First Quarter 2022 Financial Results
April 20, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
April 12, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
April 12, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022
April 11, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
March 31, 2022
From
Personalis, Inc.
Via
Business Wire
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors
March 24, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
March 23, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the Cowen 42nd Annual Health Care Conference
February 23, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
February 15, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Fourth Quarter and Full-Year Financial Results
February 10, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 01, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
January 06, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate in the 24th Annual Needham Virtual Growth Conference
December 28, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
December 16, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference
November 18, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis Named to Inc.'s 2021 Best-Led Companies List
November 12, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 11, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Third Quarter 2021 Financial Results
November 04, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
November 02, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform
October 26, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
October 26, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Third Quarter Financial Results on November 4, 2021
October 21, 2021
From
Personalis, Inc.
Via
Business Wire
Personalis Expands Leadership Team With Appointment of Robert Bruce, Vice President of Reimbursement
October 13, 2021
From
Personalis, Inc.
Via
Business Wire
Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing
October 12, 2021
From
Personalis Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.